Aurobindo Pharma Limited, a leading global pharmaceutical company, has announced its financial results for the fourth quarter of FY25, highlighting a solid performance across key business segments and markets. The company reported a 10.6% year-on-year (YoY) increase in revenue from operations, totaling INR 8,382 crore. This growth was underpinned by notable expansion in the formulations business in the US and Europe, further strengthening the presence of Aurobindo Pharma in its core markets.
Robust Growth in Key Geographies
The US formulations segment remained the largest contributor for Aurobindo Pharma, registering a 13.5% YoY rise to INR 4,072 crore (~USD 470 million). This performance reaffirmed the company’s strong position in the US, a critical geography for its operations. Similarly, the Europe formulations business demonstrated robust momentum with a 17.2% YoY increase, amounting to INR 2,147 crore (~EUR 236 million).
While the growth market segment posted a marginal YoY decline of 7.8% to INR 786 crore (~USD 91 million), other verticals performed notably well. The Antiretroviral (ARV) business experienced a significant 29.4% YoY growth to INR 308 crore (~USD 36 million), further supporting Aurobindo Pharma’s diversified global portfolio. Meanwhile, the Active Pharmaceutical Ingredients (API) segment delivered steady growth of 5.0% YoY, reaching INR 1,069 crore (~USD 124 million).
Profitability and R&D Highlights
On the profitability front, Aurobindo Pharma posted an EBITDA before R&D expenses of INR 2,202 crore, with a corresponding margin of 26.3%. EBITDA before forex and other income stood at INR 1,792 crore, yielding a 21.4% margin. This reflects the company’s operational efficiency and focus on sustainable profitability.
Research and Development (R&D) remains a strategic focus area for Aurobindo Pharma, with investments including depreciation totaling INR 423 crore—representing 5.0% of overall revenues. In a notable regulatory achievement, the company received final approval for five Abbreviated New Drug Applications (ANDAs) from the USFDA, including two that had earlier been tentatively approved.
| Segment | Revenue (INR crore) | YoY Growth (%) |
| Total Revenue from Operations | 8,382 | 10.6% |
| US Formulations | 4,072 (~USD 470 mn) | 13.5% |
| Europe Formulations | 2,147 (~EUR 236 mn) | 17.2% |
| Growth Markets | 786 (~USD 91 mn) | -7.8% |
| Antiretroviral (ARV) Business | 308 (~USD 36 mn) | 29.4% |
| Active Pharmaceutical Ingredients | 1,069 (~USD 124 mn) | 5.0% |
| EBITDA (Before R&D) | 2,202 | – |
| EBITDA (Before Forex & Other Income) | 1,792 | – |
| R&D Spend (incl. depreciation) | 423 | – |
| Net Profit | 903 | – |
The company concluded the quarter with a net profit of INR 903 crore. Both Basic and Diluted Earnings Per Share (EPS) stood at INR 15.56.
Commenting on the quarterly results, the management stated, “We are pleased with the strong financial performance in Q4FY25, driven by sustained growth in our core geographies and a healthy product pipeline. The approvals from the USFDA reinforce our regulatory capabilities and commitment to quality. We remain focused on expanding our global presence and delivering value to stakeholders through innovation, operational excellence, and patient-centric solutions.”
Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.
